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Rationale: The primary cause of morbidity and mortality in CF is progressive lung
disease associated with PA infection. New inhaled anti-PA antibiotics are needed
to slow lung disease progression.
Methods: This open label trial included patients with CF and PA who previously
participated in one of two double blind, placebo controlled trials. In this study,
patients (N = 274; mean age 28.5 years; range 8 to 74) received 75mg AZLI, a
novel formulation of aztreonam, using the PARI eFlow® Electronic Nebuliser (BID
or TID) for up to nine courses (28 days on therapy, followed by 28 days off) over
18 months. Concomitant routine CF therapies were allowed. Efﬁcacy endpoints
included change in pulmonary function (FEV1) and weight.
Results: All patients have completed study participation; median time on study was
507 days. Mean percent change in weight from baseline (Visit 1) to end of course
9 was 3.24% for BID and 3.57% for TID. Mean percent change in FEV1 from
baseline to end of course 9 was 1.3% for BID and 4.0% for TID. Mean changes in
FEV1 from baseline were positive after all nine courses for BID and TID.
Conclusions: Patients experienced improvements (compared to study baseline) in
FEV1 and weight after 9 courses with either AZLI BID or TID, but TID results
were consistently superior. Repeated treatment with AZLI is effective in improving
lung function and weight (on average) in CF patients with moderate to severe lung
disease.
Supported by: Gilead Sciences, Inc.
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Background: Identiﬁcation of DRPA has increased and is associated with accelerated
progression of lung disease caused by chronic airway infection. AZLI is an inhaled
antibiotic in development for patients with CF. The clinical efﬁcacy of a 28-day
course of AZLI in patients with DRPA identiﬁed before treatment has been evaluated
in two Phase 3 double-blind, multicenter, randomized, placebo-controlled studies. In
study AIR-CF1, patients received AZLI following a minimum 28-day period without
antipseudomonal antibiotics. In AIR-CF2, patients received AZLI immediately after a
28-day course of tobramycin inhalation solution.
Results: Patients treated with 75mg AZLI TID demonstrated improvements in respi-
ratory symptoms, pulmonary function, and sputum PA density, regardless of whether
DRPA was present. In addition, susceptibility data at the end of the treatment course
suggest that AZLI increases tobramycin susceptibility of PA isolates and does not
induce antibiotic resistance.
Conclusion: The increasing presence of DRPA has created an unmet therapeutic need
for new inhaled antibiotic options. AZLI TID appears to be active against DRPA and
thus addresses this need.
Supported by: Gilead Sciences
Clinical efﬁcacy outcomes in AIR-CF1//AIR-CF2
N Mean Change in:
CFQ-R Respiratory
Symptoms Score
Percent FEV1 (L) log10 Sputum PA
CFU density
Placebo
No DRPA* 33//24 −1.30//0.48 −0.80//1.50 0.02//0.13
DRPA 43//47 −0.65//-1.11 −3.05//-4.46 −0.12//0.36
AZLI TID
No DRPA 24//26 10.53//2.78 7.95//5.25 −2.34//-0.22
DRPA 45//37 6.67//2.93 9.51//3.40 −1.35//-0.42
*DRPA resistance to at least 1 antibiotic in 2 of the 3 classes tested
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Rationale: New inhaled anti-PA antibiotics are needed to slow progression of lung
disease in CF. Adherence to inhaled therapies is crucial to ensure treatment beneﬁt.
Methods: This ongoing open label trial enrolled 274 patients who previously
participated in one of two phase 3 trials (AIR-CF1/2). Patients received 75mg
AZLI (BID or TID) in up to nine courses (28 days on/28 days off therapy) over
18 months using the PARI eFlow® Electronic Nebulizer (2−3 minute dosing time).
Relative adherence (RA) was calculated as vials used as a percentage of the
number prescribed. A patient was considered adherent if RA  80%. Average
within course change from baseline (over ﬁrst 3 cycles) in FEV1% predicted and
respiratory symptoms (CFQ-R) was evaluated for patients originating from AIR-
CF2 (randomized comparison of BID and TID). Results for the ﬁrst 6 AZLI cycles
are also presented.
Results: Mean RA was  94% with  89% of patients compliant for each of the
ﬁrst 3 AZLI cycles, with no difference between regimens. Degree of adherence is
supported by the observed dose response. Over the ﬁrst 3 courses, FEV1% predicted
and CFQ-R improvements were greater for TID compared to BID (7.0% vs 4.2%,
p = 0.01; 5.9 vs 1.9, p = 0.04, respectively).
Conclusions: Adherence to BID and TID AZLI therapy was high and maintained
for multiple cycles. BID dosing was beneﬁcial, but TID results were consistently
better. Repeated treatment with AZLI is effective in CF patients with moderate to
severe lung disease.
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Lancovutide (Moli1901) interacts with plasma and organelle membranes, where
it activates an alternative chloride channel by elevating intracellular calcium. Ca-
activated alternative Cl-efﬂux in the lower airways of CF patients may compensate
for reduced or absent CFTR function.
In this ICH/GLP conforming chronic toxicity study, beagle dogs received daily
inhalations of lancovutide at 0, 70, 140, or 210 mg/kg during 39 weeks (4m/4f
per group). Additional 2 males and 2 females of the control and high dose group
were assigned for an 8 week recovery period post treatment. All animals survived
to the end of the treatment or recovery periods and no clinical signs attributable
to lancovutide were observed. No treatment-related ophthalmoscopic changes or
changes of respiratory function parameters were observed. An increased incidence
of ventricular premature complexes was seen in high dose animals during week 1 of
treatment only, whereas no further abnormalities were observed at later stages. There
were no effects on hematology, clinical biochemistry, urinalysis, organ weights or
macroscopic ﬁndings considered to be related to lancovutide.
Minimal to moderate histiocytosis at the paracortex in the tracheobronchial lymph
node was recorded at all dose groups. In addition, minimal to slight accumulation
of histiocytes at the septum in the lung was recorded in middle and high dose
animals. Both ﬁndings persisted during the recovery period in high dose animals.
In the absence of any related inﬂammatory or degenerative lesion, the observed
alterations were unlikely to be of adverse nature. All other microscopic ﬁndings
were within the normal range.
The NOAEL in beagle dogs was estimated to be 140mg/kg/day, representing app.
30−50 times the maximum daily dose currently used in late Phase II clinical trials.
Supported by: AOP Orphan Pharmaceuticals AG, Vienna, Austria.
